SCHEDULE: Deerfield Management Adjusts BiomX Inc. Stake

Deerfield Management entities reported recent warrant exercises, preferred stock conversions, and open market sales of BiomX Inc. common stock.

Summary

• Deerfield Private Design Fund V and Deerfield Healthcare Innovations Fund II exercised warrants for 66,242 shares each on May 27, 2026.
• The funds converted 47,957 shares of Series X Preferred Stock each into 252,397 shares of common stock on May 28, 2026.
• Reporting persons sold a total of 99,112 shares in open market transactions on May 27, 2026, at a weighted average price of $1.4624 per share.
• Following these transactions, the reporting group maintains beneficial ownership of 889,928 shares, representing 8.09% of BiomX Inc. common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while the institutional holder is trimming its position, it is simultaneously converting preferred securities into common stock, suggesting a shift in the nature of their holding rather than a full exit.

Positives

• The exercise of warrants and conversion of preferred stock indicates continued long-term investment interest from a major institutional holder.
• The company successfully increased its common stock float through the conversion of preferred securities.

Negatives

• The reporting persons executed open market sales of 99,112 shares, which may exert downward pressure on the stock price in the short term.

Risks

• The warrants held by the reporting persons are subject to a 9.99% Beneficial Ownership Limitation, which restricts the ability of the holders to exercise warrants if it would cause their total ownership to exceed this threshold.
• Future sales of common stock by major institutional holders could negatively impact market liquidity and share price.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, but notes that the reporting persons continue to hold a significant equity position in the issuer.

Management Comments

• The reporting persons disclaim beneficial ownership of shares issuable upon warrant exercise to the extent that such exercise would exceed the 9.99% Beneficial Ownership Limitation.

Industry Context

StockSavvy.ai notes that institutional rebalancing, such as the conversion of preferred stock to common stock followed by partial divestment, is a common practice for healthcare-focused investment firms managing liquidity across their portfolios.

Comparison to Industry Standards

• The 8.09% ownership stake remains significant, aligning with typical activist or long-term institutional holding patterns in the biotechnology sector.
• The use of Beneficial Ownership Limitations is a standard governance mechanism in private-to-public transition financing.

Stakeholder Impact

• Shareholders may experience minor volatility due to the reported open market sales.
• The conversion of preferred stock increases the total common stock outstanding, potentially diluting existing shareholders slightly.

Next Steps

• Continued monitoring of future Form 4 or Schedule 13D filings to track further changes in Deerfield Management's position.

Key Dates

Recommendation

The filing reflects standard portfolio management by a major shareholder. The conversion of preferred stock to common stock is a positive sign of long-term commitment, while the small sale of shares is likely routine rebalancing. Investors should hold and monitor for further institutional activity.

Keywords

BiomX, Deerfield Management, Schedule 13D, Warrant Exercise, Preferred Stock Conversion, Institutional Ownership